RXRXRECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 8.26 $ -0.59 (-6.65 %)    

Friday, 31-May-2024 15:59:58 EDT
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 8.28
$ 8.92
$ 8.22 x 100
$ 8.28 x 100
$ 8.22 - $ 9.19
$ 4.97 - $ 16.75
6,518,092
na
1.95B
$ 2.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-23-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jim-cramer-offers-his-take-on-corning-calls-this-healthcare-stock-a-terrific-spec

Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "...

 recursion-pharmaceuticals-stock-surges-10-as-nvidia-powered-supercomputer-completion-sparks-investor-optimism

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking...

Core News & Articles

 Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today anno...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 nvidia-backed-recursion-pharmaceuticals-stock-is-up-on-q1-earnings-everything-you-need-to-know

Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzi...

 recursion-pharmaceuticals-q1-2024-gaap-eps-039-beats-042-estimate-sales-13491m-beat-12650m-estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimat...

 jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner

Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and C...

 cathie-woods-ark-invest-sells-20m-coinbase-shares-as-bitcoin-trades-over-70k-buys-palantir-sells-nvidia-stock

On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technolog...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION